These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11602149)

  • 21. A frequent gene polymorphism affecting the heart-rate response to carvedilol.
    Eschenhagen T
    Pharmacogenomics; 2013 Jan; 14(2):115-8. PubMed ID: 23327570
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of Beta-blockers as first-line therapy in hypertension.
    De Caterina AR; Leone AM
    Curr Atheroscler Rep; 2011 Apr; 13(2):147-53. PubMed ID: 21207202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
    vom Dahl J; Schotten U; Sasse A
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S48-53. PubMed ID: 10535047
    [No Abstract]   [Full Text] [Related]  

  • 24. [Use of the new beta-adrenoblockader Corgard in ischemic heart disease and arterial hypertension].
    Ostapiuk FE; Khvoĭnitskiĭ VA
    Sov Med; 1984; (5):87-9. PubMed ID: 6147019
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of carvedilol on seizure induction during electroconvulsive therapy procedure.
    Syed N
    J ECT; 2009 Mar; 25(1):60. PubMed ID: 18978602
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of group I pulmonary arterial hypertension with carvedilol is safe.
    Grinnan D; Bogaard HJ; Grizzard J; Van Tassell B; Abbate A; DeWilde C; Priday A; Voelkel NF
    Am J Respir Crit Care Med; 2014 Jun; 189(12):1562-4. PubMed ID: 24930531
    [No Abstract]   [Full Text] [Related]  

  • 27. Significance of combined angiotensin II receptor blocker and carvedilol therapy in patients with congestive heart failure and arginine variant.
    Iwata A; Miura S; Nishikawa H; Kawamura A; Matsuo Y; Sako H; Kumagai K; Matsuo K; Saku K
    J Cardiol; 2006 Jan; 47(1):1-7. PubMed ID: 16475467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
    Torp-Pedersen CT;
    Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
    [No Abstract]   [Full Text] [Related]  

  • 30. Controlled-release carvedilol: a concluding perspective.
    Packer M
    Am J Cardiol; 2006 Oct; 98(7A):67L-69L. PubMed ID: 17023235
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O; Ertem B; Altun A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):310-3. PubMed ID: 21543293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
    Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
    Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statin.
    Bell DS; McGill JB; Fonseca VA
    Endocr Pract; 2007; 13(7):808-9. PubMed ID: 18194941
    [No Abstract]   [Full Text] [Related]  

  • 34. [Field study: long-term antihypertensive therapy with the beta blocker nadolol in a once-a-day dosage - an outpatient study of Swiss medical practices].
    Bertel O; Conen D; Renggli I
    Schweiz Rundsch Med Prax; 1983 Feb; 72(8):264-8. PubMed ID: 6132374
    [No Abstract]   [Full Text] [Related]  

  • 35. [Comprehensive anti-adrenergic therapy. It can save the weak heart].
    MMW Fortschr Med; 2001 Jan; 143(4):45. PubMed ID: 11219285
    [No Abstract]   [Full Text] [Related]  

  • 36. [Efficacy of ramipril, carvedilol, and trimetazidine MR in improvement of quality of life of patients after myocardial infarction].
    Gafurova RM; Abdullaev AA; Kadieva IA; Islamova UA; Mutalipov KhM
    Kardiologiia; 2010; 50(12):15-8. PubMed ID: 21591386
    [No Abstract]   [Full Text] [Related]  

  • 37. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
    Sica DA
    Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
    [No Abstract]   [Full Text] [Related]  

  • 39. [Selecting the optimal dose of a new antihypertensive agent. Its application to tertatolol].
    Amabile G; Serradimigni A; Granier J
    Ann Med Interne (Paris); 1987; 138 Suppl 1():27-30. PubMed ID: 2884913
    [No Abstract]   [Full Text] [Related]  

  • 40. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy.
    Kumar A; Choudhary G; Antonio C; Just V; Jain A; Heaney L; Papp MA
    Am Heart J; 2001 Sep; 142(3):512-5. PubMed ID: 11526366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.